Rome: Cardiologists treating Italy’s ageing patients have a fresh set of tools on the horizon after the European Medicines Agency’s scientific committee recommended three new cholesterol drugs for approval, part of a busy July meeting that endorsed a dozen medicines in total. The decisions, taken by the agency’s human medicines committee, now pass to the European Commission for the formal marketing authorisations that clear the way to pharmacy shelves.
All three target the same stubborn problem: high levels of so-called bad cholesterol that drive heart attacks and strokes, still the leading cause of death across the continent. One, a monthly injection called Lyrokaul, can be self-administered at home, sparing patients repeat clinic visits. The other two, Evlarco and Ubeslo, are daily tablets that offer an oral alternative for people who struggle with existing therapies or cannot bring their numbers down with statins alone.
For a country such as Italy, where cardiovascular disease weighs heavily on hospitals, the appeal is practical. A treatment patients can take themselves eases the burden on stretched clinics, while a wider menu of options lets doctors tailor therapy to individuals who react badly to older drugs. The committee also backed extensions for eight medicines already on the market, broadening the conditions they can treat.
A recommendation is not the same as availability. Once the Commission grants authorisation, each member state must still decide whether its health service will pay for the new drugs and at what price, a process that can stretch on for months and produces stark differences between wealthier and poorer countries. Patients in one capital may gain access long before those a few hundred kilometres away, a gap that campaigners have long criticised as unfair.
Cost will dominate those national talks. Novel cholesterol therapies typically arrive with price tags well above generic statins that cost pennies a day, forcing health systems to weigh clear clinical benefit against tight budgets. Regulators judge safety and efficacy; they do not set prices, and the value-for-money argument now shifts to national authorities and insurers.
Independent experts welcomed the additions but urged perspective. More options help the minority of patients poorly served by current drugs, they note, yet the biggest gains in heart health still come from cheaper, unglamorous measures: getting more people to take the statins already available, curbing smoking and improving diets. The agency published the outcomes in its meeting highlights, and the Commission’s endorsement is expected in the coming weeks. For clinicians in Rome and beyond, the practical question is less whether the drugs work than whether the patients who need them will actually be able to get them.
